AMX-500 is under clinical development by Amunix Pharmaceuticals and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AMX-500’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMX-500 is under development for the treatment of metastatic castration resistant prostate cancer (mCRPC). The therapeutic candidate is being developed based on the PRO-XTEN technology. It is administered through intravenous route in the form of solution.
Amunix Pharmaceuticals overview
Amunix Pharmaceuticals (Amunix) is a biotechnology company that discovers and develops long-acting protein-based therapeutics. The company develops protein and peptide therapeutics. Amunix uses its proprietary technology platform XTEN, a proprietary recombinant polypeptide that consists of naturally-occurring hydrophilic amino acids. The company’s product pipeline includes VRS-317, NB1001, NB1002, BIVV-1001, BIVV-1002, AMX-268, and others. Amunix’s develops technologies based on XTEN, a hydrophilic polymer comprised of natural amino acids that can be attached to therapeutic peptides, proteins and small molecules and it offers products for the treatment of hemophilia, diabetes, short bowel syndrome, NASH, Oncology and lipodystrophy. The company partners with biotechnology and pharmaceutical companies. Amunix is headquartered in Mountain View, California, the US..
For a complete picture of AMX-500’s drug-specific PTSR and LoA scores, buy the report here.